In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacological MEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 % of primary AML samples. Growth inhibition was due to G(1)-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70( S6K ) kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both "vertical" (i.e., inhibition of RAF and MEK along the MAPK pathway) and "lateral" (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies / Ricciardi, Maria Rosaria; Scerpa, MARIA CRISTINA; Bergamo, P; Chiaretti, Sabina; Tavolaro, Simona; Mascolo, Mg; Abrams, Sl; Steelman, Ls; Tsao, T; Marchetti, A; Del Bufalo, D; Cognetti, F; Foa, Roberto; Andreeff, M; Mccubrey, Ja; Tafuri, Agostino; Ciuffreda, Laura; Petrucci, MARIA TERESA; Konopleva, Marina; Milella, MICHELE STANISLAW. - In: JOURNAL OF MOLECULAR MEDICINE. - ISSN 0946-2716. - ELETTRONICO. - 90:10(2012), pp. 1133-1144. [10.1007/s00109-012-0886-z]

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

RICCIARDI, Maria Rosaria;SCERPA, MARIA CRISTINA;CHIARETTI, sabina;TAVOLARO, SIMONA;Cognetti F;FOA, Roberto;TAFURI, Agostino;CIUFFREDA, LAURA;PETRUCCI, MARIA TERESA;KONOPLEVA, MARINA;MILELLA, MICHELE STANISLAW
2012

Abstract

In hematological malignancies, constitutive activation of the RAF/MEK/ERK pathway is frequently observed, conveys a poor prognosis, and constitutes a promising target for therapeutic intervention. Here, we investigated the molecular and functional effects of pharmacological MEK inhibition in cell line models of acute myeloid leukemia (AML) and freshly isolated primary AML samples. The small-molecule, ATP-non-competitive, MEK inhibitor PD0325901 markedly inhibited ERK phosphorylation and growth of several AML cell lines and approximately 70 % of primary AML samples. Growth inhibition was due to G(1)-phase arrest and induction of apoptosis. Transformation by constitutively active upstream pathway elements (HRAS, RAF-1, and MEK) rendered FDC-P1 cells exquisitely prone to PD0325901-induced apoptosis. Gene and protein expression profiling revealed a selective effect of PD0325901 on ERK phosphorylation and compensatory upregulation of the RAF/MEK and AKT/p70( S6K ) kinase modules, potentially mediating resistance to drug-induced growth inhibition. Consequently, in appropriate cellular contexts, both "vertical" (i.e., inhibition of RAF and MEK along the MAPK pathway) and "lateral" (i.e., simultaneous inhibition of the MEK/ERK and mTOR pathways) combination strategies may result in synergistic anti-leukemic effects. Overall, MEK inhibition exerts potent growth inhibitory and proapoptotic activity in preclinical models of AML, particularly in combination with other pathway inhibitors. Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective targeted strategies for the treatment of AML.
2012
01 Pubblicazione su rivista::01a Articolo in rivista
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies / Ricciardi, Maria Rosaria; Scerpa, MARIA CRISTINA; Bergamo, P; Chiaretti, Sabina; Tavolaro, Simona; Mascolo, Mg; Abrams, Sl; Steelman, Ls; Tsao, T; Marchetti, A; Del Bufalo, D; Cognetti, F; Foa, Roberto; Andreeff, M; Mccubrey, Ja; Tafuri, Agostino; Ciuffreda, Laura; Petrucci, MARIA TERESA; Konopleva, Marina; Milella, MICHELE STANISLAW. - In: JOURNAL OF MOLECULAR MEDICINE. - ISSN 0946-2716. - ELETTRONICO. - 90:10(2012), pp. 1133-1144. [10.1007/s00109-012-0886-z]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/439318
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 29
social impact